Phase 2 Melanoma Trial, Recruiting NCT06466434 Sponsor: M.D. Anderson Cancer Center Condition: Melanoma
Back to Melanoma

Phase 2 Melanoma Trial, Recruiting

NCT06466434
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who speak English
  • People with a body mass index (BMI) between 18.5 and 45
  • People whose cancer has not significantly limited their ability to carry out daily activities (this is measured using a standard scale called ECOG — confirm with trial site what score of 0 or 1 means for your situation)
  • People who have been diagnosed with advanced (stage III or IV) melanoma that cannot be surgically removed, including certain types such as skin, eye, hand/foot, or mucosal melanoma. People with brain involvement that is not causing symptoms may also be eligible.
  • People who are about to start a first-line standard treatment using immune checkpoint therapy (a type of cancer treatment that helps the immune system fight cancer) for melanoma that has spread. Having had certain treatments before, in an earlier preventive setting, may still be allowed.
  • People who are able to return to MD Anderson Cancer Center for check-ups and scans (though the immune therapy itself may be received at a local clinic)
  • People whose cancer can be measured on scans according to standard criteria (a small number of people without measurable disease may also be considered)
  • Women who are able to become pregnant must have a negative pregnancy test within one week of starting the dietary part of the study
  • People who are willing to eat the foods provided as part of the study diet (with some adjustments based on personal food preferences)
  • People who are willing to attend scheduled visits, have blood drawn, and provide stool samples

Who may not be able to join:

  • People who have already received immune checkpoint therapy for melanoma that has spread
  • People with a history of inflammatory bowel disease, removal of the entire colon, or weight-loss (bariatric) surgery
  • People currently taking steroid medications above a certain daily dose (equivalent to more than 10 mg of prednisone per day)
  • People whose doctor determines that the study diet is medically unsuitable for them
  • People who follow major dietary restrictions, such as a vegan, ketogenic, or extended fasting diet, or who have relevant food allergies or coeliac disease
  • People with insulin-dependent diabetes or a condition that requires a specific type of medication called bile acid sequestrants
  • People who are unable or unwilling to take part in the study procedures
  • People who have used intravenous antibiotics in the past month, or oral antibiotics in the past two weeks
  • People who regularly take supplements containing prebiotics, fibre, or probiotics and are unwilling or unable to stop taking them for the study
  • People who currently smoke, drink more than 14 alcoholic drinks per week, or use illicit drugs
  • People who are currently pregnant, planning to become pregnant, or breastfeeding
  • People who have another cancer that requires systemic treatment (other than hormonal therapy)
  • People who have cognitive impairment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Erez Baruch, MD,PHD, M.D. Anderson Cancer Center

Phone: 713-745-5530

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
30 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Evaluate the effect of dietary intervention on the abundance of Faecalibacterium in stool samples from baseline.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov